OHTUVAYRE
GrowthNDAINHALATIONSUSPENSION
Approved
Jun 2024
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
4/8 — Partial
OHTUVAYRE by Verona Pharma is pde3 and pde4 enzymes. First approved in 2024.
Drug data last refreshed 5h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OHTUVAYRE (ensifentrine) is a phosphodiesterase 3 inhibitor administered via inhalation suspension for the treatment of respiratory conditions. It represents a small-molecule therapeutic targeting PDE3 pathways to improve airway and pulmonary function. The drug was approved by the FDA on June 26, 2024, marking Verona Pharma's entry into the respiratory therapeutics market.
Growth17.6 years to LOE
Early-stage commercial growth phase with modest reimbursement signals; small initial team building opportunity in respiratory specialty segments.
Mechanism of Action
PDE3 and PDE4 enzymes. PDE3 primarily hydrolyzes the second-messenger molecule cyclic adenosine monophosphate (cAMP) but is also capable of hydrolyzing cyclic guanosine monophosphate (cGMP). PDE4 hydrolyzes cAMP only. Inhibition of PDE3 and PDE4 results in accumulation of intracellular levels of…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Verona Pharma is hiring 1 role related to this product
Worked on OHTUVAYRE at Verona Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.